Federal Circuit Affirms Extension of The 30 Month Hatch-Waxman Stay Preventing FDA Approval of Generic Version of Evista
Client Alert | 1 min read | 02.27.09
For the first time, the Federal Circuit has affirmed the extension of a thirty month stay under the Drug Price Competition and Patent Term Restoration Act (known as the "Hatch-Waxman Act"). The U. S. District Court for the Southern District of Indiana extended the stay because the generic company recast its product, disclosing new samples only eight months before trial was to commence and produced documents after the discovery cut-off. But a vigorous dissent claims that what the majority had done is to "effectively eliminate the statutorily required finding."
At issue in Eli Lilly & Co. v. Teva Pharms. United States, Inc ., 2009 U.S. App. LEXIS 3526 (Fed. Cir. 2009) was when, under the Hatch-Waxman Act, a trial court has the discretion to extend the thirty month stay that prevents the FDA from approving a generic drug for distribution while the branded and generic companies litigate any patent infringement issues.
Chief Judge Paul R. Michel and Judge Randall R. Rader held that District Judge Sarah Evans Barker had acted within her discretion in granting the extension, emphasizing that "Teva altered its generic [Evista] tablets late in the litigation."
Judge Sharon Prost dissented, arguing that the thirty month stay period was "a hard-won compromise" that "ceases to have meaning when district courts are able to modify the stay without articulating why the narrow circumstances described in the statute are present."
Under the ruling, Teva has seven days to file a petition for panel rehearing or rehearing en banc.
Contacts
Insights
Client Alert | 3 min read | 12.10.24
Fast Lane to the Future: FCC Greenlights Smarter, Safer Cars
The Federal Communications Commission (FCC) has recently issued a second report and order to modernize vehicle communication technology by transitioning to Cellular-Vehicle-to-Everything (C-V2X) systems within the 5.9 GHz spectrum band. This initiative is part of a broader effort to advance Intelligent Transportation Systems (ITS) in the U.S., enhancing road safety and traffic efficiency. While we previously reported on the frustrations with the long time it took to finalize rules concerning C-V2X technology, this almost-final version of the rule has stirred excitement in the industry as companies can start to accelerate development, now that they know the rules they must comply with.
Client Alert | 6 min read | 12.09.24
Eleven States Sue Asset Managers Alleging ESG Conspiracy to Restrict Coal Production
Client Alert | 3 min read | 12.09.24
New York Department of Labor Issues Guidance Regarding Paid Prenatal Leave, Taking Effect January 1
Client Alert | 4 min read | 12.06.24